Abstract Details

Title Area Deprivation Index and Progression to Dementia

Topic Behavioral and Cognitive Neurology

Presentation(s) S2 - Behavioral Neurology (2:12 PM-2:24 PM)

Poster/Presentation
Number 007

Background

A limited number of studies support that neighborhood deprivation may contribute to the risk for cognitive impairment, even independently of individual-level socioeconomic measures and other established dementia risk factors.

Objective

To investigate the association of the area deprivation index (ADI), as assigned at the census block group-level, with progression to dementia in cognitively unimpaired at baseline participants (≥50 years old) of the population-based Mayo Clinic Study of Aging (MCSA).

Design/Methods ADI is a novel, validated, composite measure of neighborhood socioeconomic disadvantage that uses 17 census measures capturing education, employment, income, poverty, and housing characteristics; the census block group (i.e., the closest approximation to a "neighborhood") was the geographic unit of construction. ADI is publicly available (Neighborhood Atlas®, University of Wisconsin, School of Medicine and Public Health). Higher ADI scores indicate greater neighborhood socioeconomic deprivation. MCSA is an age/sex stratified random sample of Olmsted County (MN) residents. The study population consisted of 4,118 participants, with available ADI ranking values relative to the state for 2015 and at least one visit in 2008 – 2018. Cox proportional hazards models were fit to assess progression to dementia, adjusting for sex, education, and apolipoprotein E ε4 allele status, using age as the time scale.

Results

Participants' mean age (standard deviation (SD)) was 72.0 (10.5) years, and 49.5% were males. 293 participants progressed to dementia during a mean (SD) follow-up of 4.7 (3.4) years. Living in the 20% most (vs. 20% least) socioeconomically disadvantaged neighborhoods relative to the state was associated with a higher risk for progression to dementia (HR=1.56, 95%CI (1.031-2.365), p=0.035).

Conclusions Census block group-level neighborhood disadvantage was associated with increased risk for progression to dementia, even in a well-resourced region, such as Olmsted County, MN. Continued research is needed to understand the potential association pathways involved, which are expected to be very intricate.

Authors/Disclosures
Maria Vassilaki, MD, PhD (Mayo Clinic, Department of Quantitative Health Sciences) PRESENTER	The institution of Dr. Vassilaki has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for F. Hoffmann-La Roche Ltd . Dr. Vassilaki has stock in Abbott Laboratories. Dr. Vassilaki has stock in Johnson and Johnson. Dr. Vassilaki has stock in Medtronic. Dr. Vassilaki has stock in Amgen. Dr. Vassilaki has stock in AbbVie. Dr. Vassilaki has stock in Merck. The institution of Dr. Vassilaki has received research support from NIH. The institution of Dr. Vassilaki has received research support from European Union/ St. Anne's University Hospital Brno, Czech Republic. The institution of an immediate family member of Dr. Vassilaki has received research support from Avobis Bio, LLC.
Jeremiah Aakre	No disclosure on file
Anna Castillo	No disclosure on file
	No disclosure on file
	No disclosure on file
Walter Kremers	No disclosure on file
Michelle M. Mielke, PhD (Wake Forest University School of Medicine)	Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LabCorp. Dr. Mielke has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Siemens Healthineers. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sunbird Bio. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Mielke has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novo Nordisk.
Yonas E. Geda, MD (Barrow Neurological Institute)	The institution of Dr. Geda has received research support from NIH.
Mary M. Machulda, PhD (Mayo Clinic)	The institution of Dr. Machulda has received research support from NIH.
Rabe' Alhurani, MBBS (Loyola University Medical Center)	Dr. Alhurani has nothing to disclose.
Jonathan Graff-Radford, MD, FAAN	Dr. Graff-Radford has received personal compensation for serving as an employee of Mayo Clinic. Dr. Graff-Radford has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NINDS/NIH. The institution of Dr. Graff-Radford has received research support from NIH. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Cognition therapeutics.
Prashanthi Vemuri, PhD (Mayo Clinic)	The institution of Dr. Vemuri has received research support from NIH.
Val J. Lowe, MD (Mayo Clinic)	Dr. Lowe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AVID Radiopharmaceutical. Dr. Lowe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Inc. The institution of Dr. Lowe has received research support from AVID Radiopharmaceuticals.
Clifford R. Jack, Jr., MD (Mayo Clinic)	The institution of Dr. Jack has received research support from NIH. The institution of Dr. Jack has received research support from Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic.
David S. Knopman, MD, FAAN (Mayo Clinic)	Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
Ronald C. Petersen, MD, PhD, FAAN (Mayo Clinic)	Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nestle. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.